Breaking News Instant updates and real-time market news.

OBSV

ObsEva

$14.52

-0.34 (-2.29%)

09:40
09/15/18
09/15
09:40
09/15/18
09:40

ObsEva pipeline could 'propel' shares higher, Barron's says

Swiss biotech ObsEva has three "promising" women's reproductive health treatments reaching key development stages in the next few months that could pay off for investors, Simon Constable of Barron's wrote yesterday. The company's products could "propel" its share price higher and also attract takeover interest, Constable contends. The stock closed yesterday down 19c to $14.67. Reference Link

  • 01

    Oct

OBSV ObsEva
$14.52

-0.34 (-2.29%)

08/15/18
LEER
08/15/18
INITIATION
Target $25
LEER
Outperform
ObsEva resumed with an Outperform at Leerink
Leerink analyst Ami Fadia resumed coverage of ObsEva with an Outperform rating and $25 price target. The analyst believes that at current levels the stock does not fully reflect the commercial potential of its lead product linzagolix, which she believes can reach over $1B in peak sales, its additional women's health pipeline, and its more than $100M cash balance that can fund operation into 1H20, by which time she expects to get positive UF Phase 3 data readout for linzagolix.
08/15/18
08/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cision (CISN) initiated with an Outperform at William Blair. 2. ObsEva (OBSV) resumed with an Outperform at Leerink. 3. Idera Pharmaceuticals (IDRA) resumed with an Overweight at JPMorgan. 4. DTE Energy (DTE) initiated with an Equal Weight at Barclays. 5. Tellurian (TELL) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/18
HCWC
08/29/18
NO CHANGE
Target $44
HCWC
Buy
AbbVie study of elagolix reduces risk for ObsEva, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes AbbVie's (ABBV) long-term safety extension study of elagolix in women with uterine fibroids reduces risk for ObsEva (OBSV). The long-term efficacy for elagolix should bode well for future development of ObsEva's linzagolix in uterine fibroids, since both drugs are gonadotropin-releasing hormone receptor antagonists and have thus far shown comparable potency in clinical studies, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on ObsEva with a $44 price target.
09/13/18
JPMS
09/13/18
INITIATION
Target $29
JPMS
Overweight
ObsEva initiated with an Overweight at JPMorgan
JPMorgan analyst Eric Joseph started ObsEva with an Overweight rating and $29 price target. The analyst views ObsEva as an "underappreciated, emerging clinical-stage player" in the women's health space. The company has two pivotal stage assets addressing "significant commercial opportunities, and wholly owned rights in major markets," Joseph tells investors in a research note.

TODAY'S FREE FLY STORIES

12:05
09/20/18
09/20
12:05
09/20/18
12:05
General news
Libor has been moving higher »

Libor has been moving…

SKY

Skyline

$28.20

-2.405 (-7.86%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Skyline falls -7.9% »

Skyline is down -7.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

SSW

Seaspan

$8.05

-1.105 (-12.08%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Seaspan falls -12.2% »

Seaspan is down -12.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THO

Thor Industries

$92.17

-13.55 (-12.82%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Thor Industries falls -12.8% »

Thor Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTL

Mechel

$3.29

0.335 (11.34%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Mechel rises 12.8% »

Mechel is up 12.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEW

Puxin Limited

$8.51

0.94 (12.42%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
Puxin Limited rises 13.2% »

Puxin Limited is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$60.26

0.95 (1.60%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Options
Monster Beverage option volume is 3X daily average and calls lead puts 10:1 »

Monster Beverage option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COE

China Online Education

$7.00

(0.00%)

12:00
09/20/18
09/20
12:00
09/20/18
12:00
Hot Stocks
China Online Education rises 15.9% »

China Online Education is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPOA

Social Capital

$9.88

-0.05 (-0.50%)

11:55
09/20/18
09/20
11:55
09/20/18
11:55
Hot Stocks
Social Capital's Palihapitiya says no longer accepting new outside capital »

In a Medium post entitled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
09/20/18
09/20
11:55
09/20/18
11:55
Conference/Events
William Blair business services analyst holds group luncheon »

Business Services Analyst…

11:55
09/20/18
09/20
11:55
09/20/18
11:55
Conference/Events
Stephens specialty finance analyst to hold a group luncheon »

Specialty Finance Analyst…

MGTI

MGT Capital Investments

$0.00

(0.00%)

11:52
09/20/18
09/20
11:52
09/20/18
11:52
Hot Stocks
MGT Capital Investments announces partnership with MMH Blockchain »

MGT Capital Investments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTA

Axalta Coating

$30.16

0.23 (0.77%)

11:50
09/20/18
09/20
11:50
09/20/18
11:50
Options
Axalta Coating Systems attracts bullish option spreads »

Axalta Coating Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EAF

GrafTech

$20.10

1.015 (5.32%)

11:49
09/20/18
09/20
11:49
09/20/18
11:49
Recommendations
GrafTech analyst commentary  »

GrafTech selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

11:45
09/20/18
09/20
11:45
09/20/18
11:45
Options
Tandem Diabetes call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 27

    Nov

BYSI

BeyondSpring

$25.55

(0.00%)

11:44
09/20/18
09/20
11:44
09/20/18
11:44
Conference/Events
BeyondSpring management to meet with RBC Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

11:43
09/20/18
09/20
11:43
09/20/18
11:43
Conference/Events
RBC Capital healthcare tech analyst to hold analyst/industry conference call »

Healthcare Technology…

EB

Eventbrite

$0.00

(0.00%)

11:36
09/20/18
09/20
11:36
09/20/18
11:36
Syndicate
Breaking Syndicate news story on Eventbrite »

Eventbrite opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

DNR

Denbury Resources

$5.49

-0.095 (-1.70%)

11:35
09/20/18
09/20
11:35
09/20/18
11:35
Options
Denbury Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ELAN

Elanco

$0.00

(0.00%)

, LLY

Eli Lilly

$105.79

0.03 (0.03%)

11:28
09/20/18
09/20
11:28
09/20/18
11:28
Syndicate
Elanco opens at $32.25, IPO priced at $24.00 per share »

Elanco Animal Health…

ELAN

Elanco

$0.00

(0.00%)

LLY

Eli Lilly

$105.79

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 01

    Oct

  • 01

    Oct

  • 04

    Oct

  • 20

    Sep

ELAN

Elanco

$0.00

(0.00%)

, LLY

Eli Lilly

$105.64

-0.12 (-0.11%)

11:25
09/20/18
09/20
11:25
09/20/18
11:25
Syndicate
Breaking Syndicate news story on Elanco, Eli Lilly »

Elanco indicated to open…

ELAN

Elanco

$0.00

(0.00%)

LLY

Eli Lilly

$105.64

-0.12 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 01

    Oct

  • 01

    Oct

  • 04

    Oct

  • 20

    Sep

RF

Regions Financial

$19.41

0.25 (1.30%)

11:25
09/20/18
09/20
11:25
09/20/18
11:25
Options
Regions Financial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHTR

Charter

$331.64

1.88 (0.57%)

11:25
09/20/18
09/20
11:25
09/20/18
11:25
Conference/Events
FBN Securities media analyst to hold a group luncheon »

Media Analyst Routh holds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

ACHV

Achieve Life Sciences

$2.53

0.05 (2.02%)

11:25
09/20/18
09/20
11:25
09/20/18
11:25
Conference/Events
Achieve Life Sciences to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

11:25
09/20/18
09/20
11:25
09/20/18
11:25
Conference/Events
William Blair insurance analyst to hold a luncheon meeting »

Insurance Analyst Klauber…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.